Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Distinguishing late-onset neutropenia from classical primary neutropenia

Carlo Dufour • 15 Apr 2024
EBMT 2024
General

Carlo Dufour, MD, G.Gaslini Research Children’s Hospital, Genoa, Italy, discusses late-onset and long-lasting neutropenia and how it differs from classical primary neutropenia. Late-onset neutropenia is characterized by a progressive reduction of absolute lymphocyte count and a T- and B-cell profile similar to autoimmune disorders. While likely acquired, it could also have a genetic basis. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Carlo Dufour

Guidelines on the diagnosis and management of neutropenia
1:49
Guidelines on the diagnosis and management of neutropenia
Carlo Dufour • 15 Apr 2024
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
New guidelines for the management of neutropenia & challenges in this space
4:55
New guidelines for the management of neutropenia & challenges in this space
Carlo Dufour • 23 Apr 2023
BMF diagnosis with NGS and gene panels
2:17
BMF diagnosis with NGS and gene panels
Carlo Dufour • 1 Sep 2020

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals